Our mission is to accelerate the development of vaccines and immunotherapies against major global infectious diseases and cancers by decoding the human immune system.
The Human Vaccine Project is pleased to announce the enrollment of our first clinical vaccine trial. The study is the first step in a series of trials with the goal of understanding the principles of lifelong immunological protection across key demographics and global populations.
The Human Vaccines Project and Vanderbilt University Medical Center today announced that they joined forces with Illumina, Inc., to decipher the human immunome, the genetic underpinnings of the immune system.
The Human Vaccines Project is pleased to welcome Jose-Maria Fernandez to the Board of Directors. Jose-Maria is currently managing partner at Altamar Credit, Altamar Capital Partners LLC, and has held numerous posts in the public sector including most recently serving as Director General of the Spanish Treasury.
The Pioneering mRNA Biotech Company has Joined the Human Vaccines Project to Advance Fundamental Understanding of the Immune System
The Human Vaccines Project and Boehringer Ingelheim Partner To Accelerate the Development of Cancer Vaccines and Immunotherapies
Vanderbilt University Medical Center (VUMC) and the Human Vaccines Project announced that VUMC has become the Project’s first scientific hub.
Four scientific institutions – University of California, San Diego; J. Craig Venter Institute; La Jolla Institute for Allergy and Immunology; and The Scripps Research Institute – teamed to create the “Mesa Consortium,” a new scientific hub for the Human Vaccines Project.
Pfizer Inc. announced it joined the Human Vaccines Project, a public-private consortium looking to identify human immune responses associated with optimal vaccine protection.
The Human Vaccines Project announced support from the John D. and Catherine T. MacArthur Foundation to catalyze ethics and regulatory work for the Project’s human immunology-based clinical research program.